Plasmalogens in human serum positively correlate with high-density lipoprotein and decrease with aging

被引:92
作者
Maeba, Ryouta
Maeda, Tomomi
Kinoshita, Makoto
Takao, Kosuke
Takenaka, Hideki
Kusano, Jyun
Yoshimura, Nakayuki
Takeoka, Yoko
Yasuda, Daijiro
Okazaki, Tomoki
Teramoto, Tamio
机构
[1] Teikyo Univ, Sch Med, Dept Biochem, Itabashi Ku, Tokyo 1738605, Japan
[2] Teikyo Univ, Sch Med, Dept Internal Med, Tokyo 1738605, Japan
关键词
apolipoprotein A-I; antioxidant; LDL particle size; small dense LDL;
D O I
10.5551/jat.14.12
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Aim: The objective of the present study was to propose plasmalogens as a beneficial factor in human plasma by showing a highly positive correlation with high-density lipoprotein (HDL) and a significant reduction with aging. Methods: For 148 elderly subjects suspected of coronary artery disease (CAD), clinical characteristics such as coronary stenosis, hyperlipidemia, abnormal glucose tolerance, and hypertension were investigated, and serum biochemical markers including plasmalogens were determined. Results: Serum plasmalogens levels tended to fall in significant coronary stenosis and abnormal glucose tolerance. Correlative analyses among serum biochemical markers revealed that plasmalogens positively correlate with HDL-related values, particularly apolipoprotein A-I (apo A-I), and that the molar ratio of choline plasmalogen (ChoPlas) to ethanolamine plasmalogen (EtnPlas) correlates positively with low-density lipoprotein (LDL) particle size, and negatively with apo A-H and fasting triglyceride (TG) levels. Comparison of plasmalogens in elderly subjects with those of 119 healthy young subjects showed a marked decrease in serum plasmalogens levels by aging. Conclusion: These results suggest that serum plasmalogens, antioxidant phospholipids, function as a beneficial factor as well as HDL, and that the measurement of serum plasmalogens is useful in clinical diagnosis.
引用
收藏
页码:12 / 18
页数:7
相关论文
共 28 条
[1]  
BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
[2]   Plasmalogen phospholipids in plasma lipoproteins of normolipidemic donors and patients with hypercholesterolemia treated by LDL apheresis [J].
Brautigam, C ;
Engelmann, B ;
Reiss, D ;
Reinhardt, U ;
Thiery, J ;
Richter, WO ;
Brosche, T .
ATHEROSCLEROSIS, 1996, 119 (01) :77-88
[3]   Plasmalogen levels in serum from patients with impaired carbohydrate or lipid metabolism and in elderly subjects with normal metabolic values [J].
Brosche, T .
ARCHIVES OF GERONTOLOGY AND GERIATRICS, 2001, 32 (03) :283-294
[5]   DETERMINATION OF LIPID PHOSPHORUS IN NANOMOLAR RANGE [J].
CHALVARDJIAN, A ;
RUDNICKI, E .
ANALYTICAL BIOCHEMISTRY, 1970, 36 (01) :225-+
[6]   PLASMALOGEN PHOSPHOLIPIDS AS POTENTIAL PROTECTORS AGAINST LIPID-PEROXIDATION OF LOW-DENSITY LIPOPROTEINS [J].
ENGELMANN, B ;
BRAUTIGAM, C ;
THIERY, J .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 204 (03) :1235-1242
[7]   PPARα activators may be good candidates as antiaging agents [J].
Erol, A .
MEDICAL HYPOTHESES, 2005, 65 (01) :35-38
[8]   PLASMALOGEN OXIDATION IN HUMAN SERUM-LIPOPROTEINS [J].
FELDE, R ;
SPITELLER, G .
CHEMISTRY AND PHYSICS OF LIPIDS, 1995, 76 (02) :259-267
[9]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[10]   INCORPORATION OF ACETYL-COA GENERATED FROM PEROXISOMAL BETA-OXIDATION INTO ETHANOLAMINE PLASMALOGEN OF RAT-LIVER [J].
HAYASHI, H ;
OOHASHI, M .
BIOCHIMICA ET BIOPHYSICA ACTA-LIPIDS AND LIPID METABOLISM, 1995, 1254 (03) :319-325